ACTICOR BIOTECH SAS |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.336 EUR | +24.44% |
|
-91.94% | -88.41% |
| Apr. 26 | Acticor Biotech: rebound from the previous day's tumble | CF |
| Apr. 25 | Acticor Biotech: Phase 2/3 study fails | CF |
| Sales 2023 * | - | Sales 2024 * | - | Capitalization | 4.41M 4.72M |
|---|---|---|---|---|---|
| Net income 2023 * | -15M -16.04M | Net income 2024 * | -13M -13.9M | EV / Sales 2023 * | - |
| Net Debt 2023 * | 5.2M 5.56M | Net Debt 2024 * | 10.8M 11.55M | EV / Sales 2024 * | - |
| P/E ratio 2023 * |
-0.28
x | P/E ratio 2024 * |
-0.4
x | Employees | 29 |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| 1 day | +24.44% | ||
| 1 week | -91.94% | ||
| Current month | -89.53% | ||
| 1 month | -89.82% | ||
| 3 months | -92.11% | ||
| 6 months | -91.27% | ||
| Current year | -88.41% |
1 week
0.27
4.16
1 month
0.274.21
Current year
0.275.32
1 year
0.276.22
3 years
0.2711.00
5 years
0.2711.00
10 years
0.2711.00
| Managers | Title | Age | Since |
|---|---|---|---|
Gilles Avenard
FOU | Founder | - | 13-11-25 |
Eric Cohen
DFI | Director of Finance/CFO | - | - |
Adeline Meilhoc
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Gilles Avenard
FOU | Founder | - | 13-11-25 |
Catherine Boule
BRD | Director/Board Member | - | - |
Alain Munoz
CHM | Chairman | 75 | 21-06-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 0.336 | +24.44% | 1,658,205 |
| 24-04-25 | 0.27 | -92.64% | 811,570 |
| 24-04-24 | 3.67 | -5.66% | 15,700 |
| 24-04-23 | 3.89 | +1.83% | 6,270 |
| 24-04-22 | 3.82 | -8.39% | 36,758 |
End-of-day quote Euronext Paris, April 25, 2024
More quotes
Acticor Biotech is specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms.
The group has one product in Phase II/III clinical development (Glenzocimab).
Calendar
2024-04-29
- Q4 2023 Earnings Release
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.336
EUR
Average target price
10
EUR
Spread / Average Target
+2,876.19%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -88.41% | 4.71M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ALACT Stock
